HPV Positivity and Cervical Cancer
Conditions
Interventions
Normal control group:?????
HPV positivity group:HPV???
Cervical cancer group:????
Related diseases group:?????
Sponsors
Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: HPV positivity inclusion criteria: (1) Sexual life history; (2) Age range from 18 to 60 years; (3) The cervical abscess cell TCT examination excluded HSIL and infiltrating carcinoma; (4) Pathologic examination results of colposcopy; (5) Female patients who meet the diagnostic standards of traditional Chinese medicine and western medicine; (6) Volunteer as a clinical trial investigator. Cervical cancer inclusion criteria: (1) Age range from 23 to 55; (2) All patients met the diagnostic criteria for cervical cancer in the guidelines for standardized diagnosis and treatment of cervical cancer and precancerous lesions,all patients were diagnosed with cervical cancer by pathological examination and other auxiliary examinations; (3) All patients with cervical cancer FIGO clinical stage between the stage IIb - IIIb; (4) None of the patients received any other treatment or other medication within the first week of the study; (5) All patients were initially diagnosed with primary cervical cancer; (6) KPS scores of all patients were >= 70 points.
Exclusion criteria
Exclusion criteria: HPV positivity exclusion criteria: (1) Patients with poor compliance and low possibility of follow-up; (2) A woman who is pregnant or nursing; (3) Patients with serious damage of liver and kidney function and diseases of the blood system, psychosis and malignant tumor; (4) Patients participating in other clinical trials. Cervical cancer exclusion criteria: (1) Pregnant or lactating patients; (2) Patients with severe dysfunction of liver and kidney system, cardiopulmonary system, immune system and blood system; (3) Those with other malignant tumors at the same time; (4) Patients with severe mental illness cannot cooperate with researchers; (5) People who are allergic to the drugs in this study; (6) Unable to comply with the study regulations or unwilling to participate in the clinical investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HPV screening;pathology; | — |
Countries
China
Contacts
Public ContactYubo Li
Tianjin University of Traditional Chinese Medicine
Outcome results
None listed